PART I Overview We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases. Unlike conventional approaches that broadly activate the immune system, our Immuno-STAT platform is designed to selectively modulate disease-relevant T cells, enhancing efficacy while minimizing off-target effects. We believe our Immuno-STAT platform h...
Q2 FY2026 — expected 2026-09-20
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001193125-26-108287 | EDGAR | 106K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047677 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038059 | EDGAR | — |
| 2023-03-21 | 2022-12-31 | 0000950170-23-008927 | EDGAR | — |
| 2022-03-16 | 2021-12-31 | 0000950170-22-003969 | EDGAR | — |
| 2021-03-09 | 2020-12-31 | 0001564590-21-011777 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001564590-20-010212 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0001564590-19-007832 | EDGAR | — |
| 2018-03-29 | 2017-12-31 | 0001144204-18-017978 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277466 | EDGAR | 30K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107270 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069125 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127005 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-096967 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056838 | EDGAR | — |
| 2023-11-03 | 2023-09-30 | 0000950170-23-058838 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039770 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019646 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024991 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014747 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-008990 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001193125-26-128993 | EDGAR | 2K words |
| 2026-03-16 | 0001193125-26-108292 | EDGAR | — |
| 2026-02-18 | 0001193125-26-056983 | EDGAR | — |
| 2026-02-12 | 0001193125-26-047717 | EDGAR | — |
| 2025-12-19 | 0001193125-25-326925 | EDGAR | — |
| 2025-11-24 | 0001193125-25-292093 | EDGAR | — |
| 2025-11-20 | 0001193125-25-289713 | EDGAR | — |
| 2025-11-12 | 0001193125-25-277468 | EDGAR | — |
| 2025-11-06 | 0001193125-25-268135 | EDGAR | — |
| 2025-09-29 | 0000950130-25-000140 | EDGAR | — |
147 total filings indexed. 116 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001645460 |
| Ticker | CUE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report